Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
Details
Serval ID
serval:BIB_AA34DD001747
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
Journal
Neurology
ISSN
1526-632X (Electronic)
ISSN-L
0028-3878
Publication state
Published
Issued date
10/05/2016
Peer-reviewed
Oui
Volume
86
Number
19
Pages
1780-1784
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To establish the sensitivity and specificity of serum and CSF antibodies targeting the gangliosides GQ1b (GQ1bAb) in isolated ophthalmologic syndromes, such as acute ophthalmoplegia (AO) and optic neuritis (ON), caused by disorders other than Miller-Fisher syndrome (MFS).
We measured serum and CSF GQ1bAb in patients with MFS and with AO or ON caused by other disorders than MFS.
Twenty-one patients with AO (21 serum, 9 CSF), 13 with ON (13 serum, 13 CSF), and 12 with MFS (12 serum, 10 CSF) were included in the study. There were no significant differences in age, sex, and CSF findings between the AO and MFS groups. Elevated serum GQ1b titers occurred in 11 of 12 patients with MFS but in only 1 of the 34 patients without MFS. Sensitivity was 92% (95% confidence interval [CI] 62%-100%) and specificity 97% (95% CI 85%-100%). In CSF, GQ1bAb were identified in 2 of 10 patients with MFS but in none with other disorders. Sensitivity was 20% (95% CI 2%-56%) and specificity 100% (95% CI 85%-100%).
Increased serum GQ1bAb are highly specific for MFS. Measurement of GQ1bAb in CSF does not improve diagnosis.
This study provides Class III evidence that serum GQ1bAb accurately distinguish MFS from other disorders (sensitivity 92%, 95% CI 62%-100%; specificity 97%, 95% CI 85%-100%).
We measured serum and CSF GQ1bAb in patients with MFS and with AO or ON caused by other disorders than MFS.
Twenty-one patients with AO (21 serum, 9 CSF), 13 with ON (13 serum, 13 CSF), and 12 with MFS (12 serum, 10 CSF) were included in the study. There were no significant differences in age, sex, and CSF findings between the AO and MFS groups. Elevated serum GQ1b titers occurred in 11 of 12 patients with MFS but in only 1 of the 34 patients without MFS. Sensitivity was 92% (95% confidence interval [CI] 62%-100%) and specificity 97% (95% CI 85%-100%). In CSF, GQ1bAb were identified in 2 of 10 patients with MFS but in none with other disorders. Sensitivity was 20% (95% CI 2%-56%) and specificity 100% (95% CI 85%-100%).
Increased serum GQ1bAb are highly specific for MFS. Measurement of GQ1bAb in CSF does not improve diagnosis.
This study provides Class III evidence that serum GQ1bAb accurately distinguish MFS from other disorders (sensitivity 92%, 95% CI 62%-100%; specificity 97%, 95% CI 85%-100%).
Keywords
Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers/blood, Biomarkers/cerebrospinal fluid, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Female, Gangliosides/immunology, Humans, Immunoglobulin G/metabolism, Immunoglobulin M/metabolism, Immunotherapy, Male, Middle Aged, Miller Fisher Syndrome/complications, Miller Fisher Syndrome/diagnosis, Miller Fisher Syndrome/immunology, Miller Fisher Syndrome/therapy, Ophthalmoplegia/diagnosis, Ophthalmoplegia/etiology, Ophthalmoplegia/immunology, Ophthalmoplegia/therapy, Optic Neuritis/diagnosis, Optic Neuritis/etiology, Optic Neuritis/immunology, Optic Neuritis/therapy, Retrospective Studies, Sensitivity and Specificity, Young Adult
Pubmed
Create date
16/02/2016 18:53
Last modification date
20/08/2019 16:14
Usage data
